MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
174.10
+1.60
+0.93%
After Hours: 172.34 -1.76 -1.01% 19:57 12/12 EST
OPEN
173.49
PREV CLOSE
172.50
HIGH
175.08
LOW
171.27
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
185.17
52 WEEK LOW
110.04
MARKET CAP
25.54B
P/E (TTM)
15.87
1D
5D
1M
3M
1Y
5Y
1D
Nasdaq adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22
TipRanks · 11h ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 12h ago
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions
Seeking Alpha · 1d ago
Nasdaq-100 Index Reconstitution Adds Six New Companies, Removes Six Others Effective Dec. 22
NASDAQ · 2d ago
NASDAQ INC: BIOGEN, CDW CORPORATION, GLOBALFOUNDRIES , LULULEMON ATHLETICA, ON SEMICONDUCTOR, TRADE DESK WILL BE REMOVED FROM NASDAQ 100 INDEX
Reuters · 2d ago
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 2d ago
Biogen Price Target Raised to $156.00/Share From $149.00 by Morgan Stanley
Dow Jones · 2d ago
Biogen Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 2d ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.